Review
Biochemistry & Molecular Biology
Srijan Acharya, Kyeong-Man Kim
Summary: The review discusses the interaction between the brain dopaminergic and cholinergic systems in the pathogenesis and treatment of schizophrenia and Parkinson's disease, including their roles in motor plan selection, negative symptoms, and nicotine-induced protection of DAergic neurons.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Kaja Kolmancic, Nina K. Zupancic, Maja Trost, Dusan Flisar, Milica G. Kramberger, Zvezdan Pirtosek, Maja Kojovic
Summary: Switching from intermittent to continuous levodopa delivery can improve cortical maladaptive changes, reduce motor fluctuations and dyskinesias in patients with Parkinson's disease.
MOVEMENT DISORDERS
(2022)
Article
Clinical Neurology
P. A. Caro Aponte, C. A. Otalora, J. C. Guzman, L. F. Turner, J. P. Alcazar, E. L. Mayorga
Summary: The study aimed to develop and standardize an experimental model of L-DOPA-induced dyskinesia in rats, and evaluate the correlation between D2R expression and abnormal involuntary movements (AIM). The results suggest an association between D2R expression and locomotor AIMs.
Article
Biology
Abhinav Sharma, Diego Vidaurre, Jan Vesper, Alfons Schnitzler, Esther Florin
Summary: Dopaminergic medication in PD patients affects oscillatory whole-brain networks, leading to coherence within the medial and orbitofrontal cortex in the delta/theta frequency range, and a switch in beta band activity from an STN-mediated motor network to a frontoparietal-mediated one.
Review
Pharmacology & Pharmacy
Peter Kempster, Andrew Ma
Summary: A large proportion of drugs for neurological disorders are derived from naturally occurring compounds, especially plant alkaloids. The treatment of Parkinson's disease has strong botanical origins, with plant-derived substances playing a significant role. The interaction between plant compounds and animal dopaminergic systems has deep evolutionary roots.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Vladimir M. Pogorelov, Michael L. Martini, Jian Jin, William C. Wetsel, Marc G. Caron
Summary: L-DOPA is the main treatment for Parkinson's disease, but it can lead to dyskinesia over time. In this study, dopamine-depleted dopamine-transporter KO (DDD) mice were used as an acute PD model to screen novel compounds for anti-parkinsonian and L-DOPA-induced dyskinesia. The researchers found that oral stereotypies could be used as an index for LID in DDD mice.
Article
Behavioral Sciences
Yang Tan, Chi Cheng, Cong Zheng, Weiqi Zeng, Xiaoman Yang, Yu Xu, Zhaoyuan Zhang, Zhuoran Ma, Yan Xu, Xuebing Cao
Summary: The activation of striatal mGlu(2/3) receptors can attenuate the development of dyskinesia in parkinsonism rats and provide some functional improvements in LID rats by inhibiting LID-related molecular changes.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
(2023)
Article
Clinical Neurology
Diana A. Olszewska, Alfonso Fasano, Renato P. Munhoz, Carolina Candelaria Ramirez Gomez, Anthony E. Lang
Summary: This retrospective cohort study aimed to investigate the difference in the time between initial levodopa and dopamine agonist (DA) treatment and the development of disabling motor complications (MCs) in Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS). The results showed no significant difference in the duration from the first treatment to DBS assessment or surgery between patients who received levodopa and those who received a DA.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Feras Altwal, Fernando E. Padovan-Neto, Alexandra Ritger, Heinz Steiner, Anthony R. West
Summary: Research has shown that vilazodone may reduce dyskinesia in patients with Parkinson's disease without interfering with the prokinetic effects of L-DOPA, possibly through its action on 5-HT receptors.
Article
Biochemistry & Molecular Biology
Mechelle M. Lewis, Lauren J. Van Scoy, Sol De Jesus, Jonathan G. Hakun, Paul J. Eslinger, Julio Fernandez-Mendoza, Lan Kong, Yang Yang, Bethany L. Snyder, Natalia Loktionova, Sridhar Duvvuri, David L. Gray, Xuemei Huang, Richard B. Mailman
Summary: Current pharmacotherapy has limited efficacy and intolerable side effects in late-stage Parkinson's disease patients. A study was conducted to explore the efficacy of a D-1/5 dopamine agonist in these patients. Caregiver assessment was used as the primary efficacy measure, and the results showed that the D-1/5 agonist had better efficacy compared to levodopa in most patients.
Article
Clinical Neurology
Jose A. Pineda-Pardo, Alvaro Sanchez-Ferro, Mariana H. G. Monje, Nicola Pavese, Jose A. Obeso
Summary: The striatal dopaminergic deficit in Parkinson's disease follows a somatotopically related pattern, with an upper-limb onset and progression to other regions of the striatum. The denervation of the putamen was confirmed in both hemispheres and corresponding hemibodies. The findings suggest a precise somatotopic onset of nigrostriatal denervation in Parkinson's disease.
Article
Neurosciences
Waijiao Cai, Kazumasa Wakamatsu, Fabio A. Zucca, Qing Wang, Kai Yang, Niyaz Mohamadzadehonarvar, Pranay Srivastava, Hitomi Tanaka, Gabriel Holly, Luigi Casella, Shosuke Ito, Luigi Zecca, Xiqun Chen
Summary: By studying samples of substantia nigra from patients with Parkinson's disease, we found increased ratios of pheomelanin to dopamine in the melanin content, as well as reduced levels of eumelanins derived from both DOPA and dopamine. Additionally, an increase in pheomelanin relative to dopamine pheomelanin was observed in Parkinson's disease. These findings provide insights into the roles of pheomelanin and eumelanin in the pathophysiology of Parkinson's disease.
PROGRESS IN NEUROBIOLOGY
(2023)
Review
Clinical Neurology
Carissa A. Hansen, Douglas R. Miller, Stephanie Annarumma, Carley T. Rusch, Adolfo Ramirez-Zamora, Habibeh Khoshbouei
Summary: This manuscript provides a comprehensive review of treatment protocols, absorption, distribution, and drug/food interactions related to L-DOPA-induced dyskinesia, and discusses current strategies and future directions.
JOURNAL OF NEUROLOGY
(2022)
Article
Chemistry, Medicinal
Ramon Cacabelos, Ivan Carrera, Olaia Martinez, Ramon Alejo, Lucia Fernandez-Novoa, Pablo Cacabelos, Lola Corzo, Susana Rodriguez, Margarita Alcaraz, Laura Nebril, Ivan Tellado, Natalia Cacabelos, Rocio Pego, Vinogran Naidoo, Juan C. Carril
Summary: Atremorine is a novel bioproduct obtained from a genetic species of Vicia faba, acting as a potent dopamine enhancer and neuroprotective agent in Parkinson's disease. It enhances dopamine levels, influences other neurotransmitters and hormones, and potentiates the effects of conventional anti-PD drugs. The variability in response to Atremorine is highly influenced by pharmacogenetic factors, polymorphic gene variants, and its ability to modulate the pharmacoepigenetic network.
MEDICINAL RESEARCH REVIEWS
(2021)
Article
Neurosciences
Luke Li, Lei Cheng, YanYan Wang
Summary: The study examined the role of dopamine D2R isoforms, D2S and D2L, in l-dopa-induced AIMs and found that D2S contributes more than D2L to dopaminergic agonist-induced AIMs. D2L KO mice showed significantly enhanced AIMs in response to chronic treatment with l-dopa, indicating a potential role of the D2L isoform in the development of AIMs side effects. These findings provide new insights into the pathophysiology of dopaminergic drug-induced AIMs and suggest the importance of the D2S to D2L ratio in the brain in the development of these adverse effects.
Article
Neurosciences
Lauren Broom, Peter Jenner, Sarah Rose
EXPERIMENTAL NEUROLOGY
(2015)
Article
Clinical Neurology
Louise Lincoln, Ria Fisher, Michael J. Jackson, Peter Jenner, John Neumeyer, Anna W. Sromek, Andrew J. Lees, Sarah Rose
MOVEMENT DISORDERS
(2016)
Article
Multidisciplinary Sciences
Michel Modo, William R. Crum, Madeline Gerwig, Anthony C. Vernon, Priya Patel, Michael J. Jackson, Sarah Rose, Peter Jenner, Mahmoud M. Iravani
Article
Multidisciplinary Sciences
Sara Pritchard, Michael J. Jackson, Atsuko Hikima, Lisa Lione, Christopher D. Benham, K. Ray Chaudhuri, Sarah Rose, Peter Jenner, Mahmoud M. Iravani
Article
Chemistry, Medicinal
Ria Fisher, Louise Lincoln, Michael J. Jackson, Vincenzo Abbate, Peter Jenner, Robert Hider, Andrew Lees, Sarah Rose
PHYTOTHERAPY RESEARCH
(2018)
Article
Endocrinology & Metabolism
X. F. Li, M. H. Hu, S. Y. Li, C. Geach, A. Hikima, S. Rose, M. P. Greenwood, M. Greenwood, D. Murphy, L. Poston, S. L. Lightman, K. T. O'Byrne
Article
Pharmacology & Pharmacy
Maria Papathanou, Peter Jenner, Mahmoud Iravani, Michael Jackson, Kim Stockwell, Isabel Strang, Bai-Yun Zeng, Andrew C. McCreary, Sarah Rose
EUROPEAN JOURNAL OF PHARMACOLOGY
(2014)
Article
Biochemistry & Molecular Biology
Michael J. Hurley, Michael J. Jackson, LanceA. Smith, Sarah Rose, Peter Jenner
JOURNAL OF MOLECULAR NEUROSCIENCE
(2014)
Article
Clinical Neurology
Mahmoud M. Iravani, Mona Sadeghian, Sarah Rose, Peter Jenner
JOURNAL OF NEURAL TRANSMISSION
(2014)
Article
Clinical Neurology
Monika J. Brzozowski, Peter Jenner, Sarah Rose
JOURNAL OF NEURAL TRANSMISSION
(2015)
Article
Multidisciplinary Sciences
Anne Michel, Jean-Marie Nicolas, Sarah Rose, Michael Jackson, Peter Colman, Willy Brione, David Sciberras, Pierandrea Muglia, Dieter K. Scheller, Martin Citron, Patrick Downey
Article
Clinical Neurology
Andres Asser, Atsuko Hikima, Mari Raki, Kim Bergstrom, Sarah Rose, Julius Juurmaa, Villem Krispin, Mari Muldmaa, Stella Lilles, Hanna Raetsep, Peter Jenner, Sulev Koks, Pekka T. Maennisto, Pille Taba
JOURNAL OF NEURAL TRANSMISSION
(2020)
Article
Neurosciences
Ria Fisher, Atsuko Hikima, Rebecca Morris, Michael J. Jackson, Sarah Rose, Mark A. Varney, Ronan Depoortere, Adrian Newman-Tancredi
Editorial Material
Neurosciences
Luigi Zecca, Christian Pifl, Stanley Fahn, David Sulzer, Ruggero G. Fariello
Summary: By studying Parkinson's disease and the treatment with L-DOPA, Hornykiewicz improved the lives of many individuals and made significant contributions to neurology and medical science.
NPJ PARKINSONS DISEASE
(2021)
Article
Neurosciences
Erika Coletto, John S. Dolan, Sara Pritchard, Alex Gant, Atsuko Hikima, Michael J. Jackson, Christopher D. Benham, K. Ray Chaudhuri, Sarah Rose, Peter Jenner, Mahmoud M. Iravani
NPJ PARKINSONS DISEASE
(2019)